Blog

HealthDay Reporter

THURSDAY, Aug. 2, 2018 (HealthDay News) — Middle-aged people who drink moderately — no more than a glass of wine a day — may have a relatively lower risk of developing dementia later in life, researchers report.

The study, which followed 9,000 British adults for over two decades, found that both heavier drinkers and abstainers had a higher dementia risk than moderate drinkers.

Moderate drinking was defined according to the recommended drinking limits in the United Kingdom: no more than 14 “units” of alcohol per week. That translates to one medium-sized glass of wine, or roughly a pint of beer, each day.

People who were nondrinkers in middle age were 47 percent more likely to

The Trump administration has made clear it would like to remake the American health care system. There’s been the protracted battle over the Affordable Care Act. Now, there are some new moves on the future of Medicaid.

On Monday, the federal government released decisions on requests from two states to change the way they administer the health care program for low-income people.

The first decision came on lifetime caps. Kansas wanted to cut off Medicaid benefits for some people after 36 months.

At a meeting of the American Hospital Association in Washington, D.C., Seema Verma, administrator of the Centers for Medicare and Medicaid Services, made clear that she wants states to have lots of flexibility. But she also drew a

PHOENIX, March 20, 2018 (Newswire.com) – Yvette N. Banker, Founder, Banker Law Office, P.L.L.C., has joined Noticed©, an invitation-only service for distinguished professionals. Banker has been chosen as a Distinguished Lawyer™ based on peer reviews and ratings, dozens of recognitions, and accomplishments achieved throughout her career.

Banker outshines others in her field due to her extensive educational background, numerous awards and recognitions, and career longevity. Banker graduated from the University of California at Santa Barbara with a bachelor’s degree in 1995. She was accepted to the University of Denver for law school, and obtained her Juris Doctorate in 2000, after which she worked for prominent elder law attorneys in both Colorado and Arizona.

With 17 years dedicated to law, Banker brings a wealth of knowledge to her

 

A variant of vitamin B-3 may soon be a viable Alzheimer’s treatment, new research suggests.

Vitamin B-3 has previously been proposed as an alternative for treating Alzheimer’s disease.

In an older study, large doses of nicotinamide — also referred to as B-3 — reversed Alzheimer’s-related memory loss in mice.

A new study, however, focused on the effect of nicotinamide riboside (NR), which is a form of vitamin B-3, on Alzheimer’s-related brain damage in mice.

More specifically, the researchers — who were jointly led by Dr. Vilhelm A. Bohr, the chief of the National Institute on Aging’s (NIA) Laboratory of Molecular Gerontology, and Dr. Yujun Hou, a postdoctoral investigator in the laboratory — focused on how NR affects the brain’s ability to repair its DNA, a function that is